Straits Times Index
3,324.19 +2.11 (+0.06%) Nikkei
39,206.54 +168.38 (+0.43%) Hang Seng
18,163.12 -203.83 (-1.11%) FTSE 100
8,228.48 -16.89 (-0.20%) Bitcoin USD
69,412.21 -185.50 (-0.27%) CMC Crypto 200
1,438.83 -7.84 (-0.54%)
CADL Oct 2024 6.000 put
| Previous close | 1.2000 |
| Open | 1.2000 |
| Bid | 1.2000 |
| Ask | 1.9500 |
| Strike | 6.00 |
| Expiry date | 2024-10-18 |
| Day's range | 1.2000 - 1.2000 |
| Contract range | N/A |
| Volume | |
| Open interest | 7 |
GlobeNewswireFDA Grants Orphan Drug Designation for CAN-3110 for the Treatment of Recurrent High-Grade Glioma
FDA Orphan Designation provides CAN-3110 certain developmental financial incentives, with potential for up to 7 years of marketing exclusivity in the United States, if approvedCAN-3110 phase 1b data on the feasibility and safety of multiple doses of CAN-3110 will be featured in poster presentation at 2024 ASCO Annual Meeting NEEDHAM, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on deve
ZacksCandel (CADL) Stock Skyrockets 431% Year to Date: Here's Why
Candel (CADL) surges 431% in the year-to-date period, driven by positive developmental and regulatory updates from the clinical program for CAN-2409 across two different cancer indications.
ZacksCandel (CADL) Reports Upbeat Data From Lung Cancer Study
Candel's (CADL) CAN-2409 prolongs overall survival in a phase II study for treating patients with advanced non-small cell lung cancer who are non-responsive to immune checkpoint inhibitor therapy.
